Twenty-three (23) new employee invention reports (EIRs) were evaluated in FY2020 by the TTO, were filed with the NIH Office of Technology Transfer (OTT) and were assigned an official record number. Eight (8) were for biological materials and five (5) were for technologies that could be patented or at least evaluated for patenting; ten (10) patent application filings were done by a third-party CRADA collaborator. 1) MOUSE MODEL OF HERMANSKY-PUDLAK SYNDROME EIR Reference No: E-073-2020; 2) IDENTIFICATION OF THE ROLE OF UBA1 IN INFLAMMATORY DISEASE AND CANCERU.S. Patent Application No: 63/059,107. EIR Reference No: E-083-2020; 3) USE OF LAMP-1 GENE THERAPY TO TREAT LYSOSOMAL STORAGE DISORDERS U.S. Patent Application in preparation. EIR Reference No: E-146-2020; 4) SYSTEM AND METHOD FOR ESTIMATING A QUANTITY OF INTEREST BASED ON AN IMAGE OF A HISTOLOGICAL SECTION U.S. Patent Application No: 16/930,602 3rd party patent prosecution; EIR Reference No: E-212-2020; 5) HUMAN FIBROBLAST CELL LINES HETEROZYGOUS FOR GLUCOCEREBROSIDASE (GBA1) MUTATION N370S EIR Reference No: E-218-2020; 6) HUMAN FIBROBLAST CELL LINES FROM PATIENTS WITH GANGLIOSIDOSIS DISEASES EIR in preparation; 7) METHODS FOR TREATMENT OF SUBJECTS WITH PREEXISTING IMMUNITY TO VIRAL TRANSFER VECTORS CRADA SUBJECT INVENTION 3rd party patent prosecution. U.S. Patent Application No: 62/981,564; EIR Reference No: E-180-2020; 8) METHODS FOR TREATMENT OF SUBJECTS WITH PREEXISTING IMMUNITY TO VIRAL TRANSFER VECTORS CRADA SUBJECT INVENTION. 3rd party patent prosecution. U.S. Patent Application No: 62/981,555; EIR Reference No: E-179-2020; 9) METHODS FOR TREATMENT OF SUBJECTS WITH PREEXISTING IMMUNITY TO VIRAL TRANSFER VECTORS CRADA SUBJECT INVENTION. 3rd party patent prosecution. U.S. Patent Application No: 62/924,143; EIR Reference No: E-178-2020; 10) METHODS FOR TREATMENT OF SUBJECTS WITH PREEXISTING IMMUNITY TO VIRAL TRANSFER VECTORS CRADA SUBJECT INVENTION. U.S. Patent Application No: 62/624,103; EIR Reference No: E-177-2020; 11) METHODS FOR TREATMENT OF SUBJECTS WITH PREEXISTING IMMUNITY TO VIRAL TRANSFER VECTORS CRADA SUBJECT INVENTION 3rd party patent prosecution. U.S. Patent Application No: 62/829,771; EIR Reference No: E-176-2020; 12) METHODS AND COMPOSITIONS OF MMA CONSTRUCTS AND VECTORS CRADA SUBJECT INVENTION. 3rd party patent prosecution. U.S. Patent Application No: 62/513,579; EIR Reference No: E-164-2020-03; 13) METHODS AND COMPOSITIONS OF MMA CONSTRUCTS AND VECTORS CRADA SUBJECT INVENTION. 3rd party patent prosecution. U.S. Patent Application No: 62/839,761 and PCT/US2019/042073; EIR Reference No: E-164-2020-02; 14) METHODS AND COMPOSITIONS OF MMA CONSTRUCTS AND VECTORS CRADA SUBJECT INVENTION.3rd party patent prosecution. U.S. Patent Application No: 62/939, 761 and 62/839,771; EIR Reference No: E-164-2020-01; 15) Novel Adeno-associated Viral (AAV) Vectors To Treat Hereditary Methylmalonic Acidemia (MMA) Caused By Methylmalonyl-coA Mutase (MMUT) Deficiency U.S. Patent Application in preparation; EIR Reference No: E-167-2020; 16) METHODS AND COMPOSITIONS OF MMA CONSTRUCTS AND VECTORS CRADA SUBJECT INVENTION. 3rd party patent prosecution. U.S. Patent Application No: US 62/839,761, and 62/839,771; EIR Reference No: E-164-2020-00; 17) MMUT P.PRO207_LYS210DEL/ P.PRO207_LYS210DEL KNOCK-IN METHYLMALONYL-COA MUTASE (MMUT) ALLELE FOR THE STUDY OF METHYLMALONIC ACIDEMIA (MMA) EIR Reference No: E-161-2020; 18) MMUT P.G715V/ P.G715V KNOCK-IN METHYLMALONYL-COA MUTASE (MMUT) ALLELE FOR THE STUDY OF METHYLMALONIC ACIDEMIA (MMA) EIR Reference No: E-160-2020; 19) MMUT P.R106C/ P.R106C KNOCK-IN METHYLMALONYL-COA MUTASE (MMUT) ALLELE FOR THE STUDY OF METHYLMALONIC ACIDEMIA (MMA) EIR Reference No: E-159-2020; 20) HIGH CONCENTRATION METHYLCOBALAMIN (ME-CBL) OR COMBINATION OF METHYL- AND HYDROXOCOBALAMIN (ME/OH-CBL) FOR THE TREATMENT OF COBALAMIN C DEFICIENCY AND RELATED DISORDERS U.S. Patent Application in preparation. EIR Reference No: E-147-2020; 21) NOVEL ANTIBODIES AND SUPPORTING REAGENTS TO DETECT METHYLMALONYL-LYSINE, A NEW POST-TRANSITIONAL MODIFICATION (PTM) RELATED TO HEREDITARY METHYLMALONIC ACIDEMIA AND DISORDERED VITAMIN B12 METABOLISM EIR Reference No: E-132-2020; 22) ABERRANT POST-TRANSLATIONAL MODIFICATIONS (PTMS) IN METHYL- AND PROPIONIC ACIDEMIA AND A MUTANT SIRTUIN (SIRT) TO METABOLIZE PTMS U.S. Patent Application No: 62/021,179. EIR Reference No: E-054-2020; 23) STAPHYLOCOCCUS EPIDERMIDIS PAN-GENOME SEQUENCE ANALYSIS REVEALS DIVERSITY OF SKIN COMMENSAL AND HOSPITAL INFECTION-ASSOCIATED ISOLATES, EIR in preparation. Ten (10) new patent applications were filed in FY2020 based on NHGRI EIRs. In FY2020, four (4) patents were issued in the NHGRI portfolio. As of August 2020, NHGRI had forty-four (44) active patent families, fifty-nine (59) issued U.S. patents (including abandoned, expired and filed by third parties), one hundred and sixty-five (165) issued foreign patents (including abandoned, expired and filed by third parties), and sixty-two (62) pending patent applications (U.S. and foreign), including third party leads. In FY2020, NHGRI negotiated and executed seven (7) new conditional gift fund agreements with the following organizations: a research grant with Niemann Pick Canada (for research focused on Niemann Pick disease); NHGRI PI is William Pavan; two research grants with the Neuromuscular Disease Foundation (for research focused on GNE Myopathy; NHGRI PI is William Gahl, M.D., Ph.D.); a grant with the Salla Treatment and Research Foundation (for research focused on Salla disease; NHGRI PI is William Gahl, M.D., Ph.D.); a research grant from the National Tay-Sachs and Allied Diseases Association (NTSAD) (for research focused on Tay-Sachs disease); NHGRI PI is Cynthia Tifft, M.D.; a research grant with the Michael J. Fox Foundation (MJFF) (for research focused on Parkinsons disease; NHGRI PI is Ellen Sidransky, M.D.; a research grant from Aligning Science Across Parkinsons (ASAP)(for research focused on Parkinsons disease; NHGRI PI is Ellen Sidransky.Our Office also handled the electronic submission of several K99/R00, PRAT and Lasker NIH applications on behalf of postdoctoral fellows. In FY2020 we negotiated and executed two (2) new Cooperative Research and Development Agreements (CRADAs) with the following companies: 1) A Multinational, randomized, double-blind, placebo-controlled study to assess the efficacy, pharmacodynamics, pharmacokinetics, and safety of venglustat in late-onset GM2 (AMETHIST), NHGRI scientist (Cynthia Tift) (CRADA Number 2019-0157) effective June 2, 2020, with Genzyme Corporation d/b/a Sanofi Genzyme; 2) Clinical Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets related to ADHD, NHGRI scientists: Drs. Phillip Shaw and Susan Persky (CRADA Number: 2020-0079); effective May 13, 2020 with Floreo, Inc. In addition, in FY2020 we processed one hundred seventy-three (173) Material Transfer Agreements (MTAs), MTA Amendments and Information Transfer Agreements (ITAs). The vast majority of these agreements covered materials and data provided by NHGRI to outside entities and fifty-six percent (56%) of the MTAs, MTA Amendments and ITAs involved the transfer of human materials or data. We also negotiated 6 research collaboration agreements (RCAs), 40 confidentiality disclosure agreements (CDAs) and 24 standard NHGRI video/written works release agreements.